{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:17:56Z","timestamp":1791299876365,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Immune dysregulation and predisposition to malignancies are critical comorbidities in children affected with ataxia telangiectasia. In addition, these children exhibit increased toxicity to conventional cancer therapy and dose reductions have been proposed to prevent life threatening adverse effects. These modifications to the treatment regimen may result in suboptimal outcomes for these patients. Our report of 3 children with ataxia telangiectasia and cancer highlight the immense challenges in the management of these children, underlining the need for the development of novel, biological agents with reduced acute and long-term side effects in the treatment of cancers in these children.<\/jats:p>","DOI":"10.1097\/mph.0000000000001005","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T23:20:37Z","timestamp":1512170437000},"page":"483-486","source":"Crossref","is-referenced-by-count":17,"title":["Ataxia Telangiectasia and Cancer Predisposition: Challenges in Management"],"prefix":"10.1097","volume":"40","author":[{"given":"Santhosh A.","family":"Upadhyaya","sequence":"first","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajen","family":"Mody","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Walkovich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond J.","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Sandlund","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital"},{"name":"Department of Pediatrics, University of Tennessee College of Medicine, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology Oncology, Vanderbilt University Medial Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-011811-132509","article-title":"ATM and the molecular pathogenesis of ataxia telangiectasia","volume":"7","author":"McKinnon","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1007\/s11033-011-1381-2","article-title":"Association between ATM polymorphisms and cancer risk: a meta-analysis","volume":"39","author":"Shen","year":"2012","journal-title":"Mol Biol Rep"},{"key":"R3-20230918","first-page":"89","article-title":"Mortality and cancer incidence in 263 patients with ataxia-telangiectasia","volume":"77","author":"Morrell","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","article-title":"Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies","volume":"33","author":"Suarez","year":"2015","journal-title":"J Clin Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1259\/0007-1285-56-665-343","article-title":"Ataxia telangiectasia with cancer. An indication for reduced radiotherapy and chemotherapy doses","volume":"56","author":"Abadir","year":"1983","journal-title":"Br J Radiol"},{"key":"R6-20230918","first-page":"560","article-title":"Proceedings: a patient with ataxia-telangiectasia showing abnormal radiosensitivity to normal doses of irradiation","volume":"49","author":"Mann","year":"1976","journal-title":"Br J Radiol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/pbc.24696","article-title":"Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies","volume":"61","author":"Sandlund","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<491::AID-MPO5>3.0.CO;2-B","article-title":"Treatment of lymphoid malignancies in patients with ataxia-telangiectasia","volume":"31","author":"Sandoval","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00043426-200101000-00008","article-title":"Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children\u2019s cancer group report","volume":"23","author":"Cairo","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jnci\/93.2.121","article-title":"Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries","volume":"93","author":"Olsen","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1056\/NEJM199112263252602","article-title":"Incidence of cancer in 161 families affected by ataxia-telangiectasia","volume":"325","author":"Swift","year":"1991","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R13-20230918","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/11.suppl_1.S141","article-title":"Non-Hodgkin\u2019s lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials","volume":"11","author":"Seidemann","year":"2000","journal-title":"Ann Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.25621","article-title":"Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab","volume":"62","author":"Meister","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MPH.0b013e3182804d59","article-title":"Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab","volume":"35","author":"Machida","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2016-09-743112","article-title":"Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study","volume":"129","author":"Mehta","year":"2017","journal-title":"Blood"},{"key":"R17-20230918","article-title":"Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders","author":"Slack","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/bmt.2012.207","article-title":"Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL","volume":"48","author":"Ussowicz","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:18:13Z","timestamp":1695010693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001005","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}